Vir Biotechnology (NASDAQ:VIR) CEO Backer Marianne De Sells 72,559 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Backer Marianne De sold 72,559 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $9.16, for a total value of $664,640.44. Following the completion of the transaction, the chief executive officer owned 948,145 shares in the company, valued at approximately $8,685,008.20. This trade represents a 7.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Backer Marianne De also recently made the following trade(s):

• On Tuesday, February 24th, Backer Marianne De sold 14,762 shares of Vir Biotechnology stock. The shares were sold at an average price of $9.53, for a total value of $140,681.86.
• On Monday, February 23rd, Backer Marianne De sold 19,039 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total value of $141,840.55.

Vir Biotechnology Trading Up 1.2%

NASDAQ VIR traded up $0.11 on Tuesday, hitting $9.17. 1,611,116 shares of the company traded hands, compared to its average volume of 3,452,609. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -2.90 and a beta of 1.66. The business’s 50 day moving average price is $8.55 and its 200-day moving average price is $6.89. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $10.94.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.11. The company had revenue of $64.07 million for the quarter, compared to the consensus estimate of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.Vir Biotechnology’s quarterly revenue was up 417.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.76) earnings per share. As a group, sell-side analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Institutional Investors Weigh In On Vir Biotechnology

Several large investors have recently made changes to their positions in VIR. Raymond James Financial Inc. bought a new stake in Vir Biotechnology during the second quarter worth approximately $35,000. FNY Investment Advisers LLC bought a new stake in Vir Biotechnology during the third quarter worth approximately $38,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Vir Biotechnology by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after acquiring an additional 1,390 shares during the last quarter. UMB Bank n.a. increased its stake in Vir Biotechnology by 1,418.7% during the fourth quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after acquiring an additional 6,597 shares during the last quarter. Finally, Federated Hermes Inc. increased its stake in Vir Biotechnology by 153.8% during the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after acquiring an additional 4,899 shares during the last quarter. 65.32% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

VIR has been the topic of several research analyst reports. Wall Street Zen upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Evercore restated an “outperform” rating and issued a $18.00 price objective on shares of Vir Biotechnology in a research report on Tuesday, February 24th. Leerink Partners restated an “outperform” rating and issued a $20.00 price objective on shares of Vir Biotechnology in a research report on Thursday, February 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. Finally, Raymond James Financial upgraded Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price objective on the stock in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Vir Biotechnology has an average rating of “Moderate Buy” and a consensus target price of $20.44.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.